+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Kallikrein Inhibitors Market - Global Forecast 2026-2032- Product Image
Kallikrein Inhibitors Market - Global Forecast 2026-2032- Product Image
Sale

Kallikrein Inhibitors Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6117124
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Kallikrein Inhibitors Market is projected to reach USD 2.26 Billion in 2026. It is expected to continue growing at a CAGR of 14.39%, reaching USD 5.24 Billion by 2032.

Kallikrein Inhibitors: Clinical Rationale and Strategic Context

Kallikrein inhibitors are designed to modulate the kallikrein-kinin system, a biologic pathway involved in inflammation, vascular permeability, coagulation, and pain. Their clinical relevance is most established in disorders associated with excessive bradykinin activity, including hereditary angioedema, while broader investigation continues across inflammatory, cardiovascular, renal, and perioperative settings. The field combines established therapeutic concepts with ongoing work to improve selectivity, route of administration, durability, and patient access.

From Acute Rescue to Targeted Pathway Management

The landscape is shifting from reliance on episodic treatment toward more proactive pathway management. Important developments include the differentiation of plasma kallikrein and tissue kallikrein targets, the use of biomarkers and clinical history to refine treatment selection, and increasing attention to subcutaneous and oral delivery. Regulatory requirements, safety monitoring, treatment convenience, and evidence of benefit in underserved populations are becoming as important as mechanistic novelty.

Artificial Intelligence Strengthens Discovery and Clinical Execution

Artificial intelligence can support kallikrein-inhibitor development by identifying structure-activity relationships, prioritizing compounds, modeling target engagement, and integrating genomic, proteomic, and clinical data. In clinical development, machine learning may help identify patients at risk of attacks, improve trial enrichment, and detect safety signals earlier. These benefits depend on high-quality datasets, transparent validation, privacy safeguards, and continued clinician oversight; AI should augment rather than replace pharmacologic and clinical judgment.

Regional Insights Across Six Distinct Healthcare Environments

North America combines specialized allergy and immunology care with relatively mature diagnostic and reimbursement infrastructure. Europe emphasizes evidence-based assessment, cross-border regulatory coordination, and health-technology evaluation, while access can differ substantially among national systems. Asia-Pacific presents strong scientific and manufacturing capabilities alongside wide variation in diagnosis, insurance coverage, and specialist availability. Latin America is shaped by uneven access to rare-disease services and public procurement constraints. The Middle East is investing in advanced healthcare capacity but remains heterogeneous in referral networks and reimbursement. Africa faces limited specialist coverage and diagnostic infrastructure, increasing the importance of training, reliable supply chains, and locally appropriate access programs.

Group Insights: Policy Alignment, Trade, and Security Shape Adoption

ASEAN markets reflect diverse regulatory systems and healthcare capacities, making harmonized evidence and distribution partnerships valuable. BRICS countries combine substantial scientific and clinical resources with differing approval, procurement, and reimbursement pathways. The European Union benefits from coordinated scientific standards but retains national variation in funding decisions. G7 members generally have strong research ecosystems and pharmacovigilance capabilities, while cost-effectiveness and budget impact remain central. GCC countries can leverage concentrated tertiary-care networks and cross-border expertise. NATO members are relevant to resilience planning because continuity of specialty medicines depends on secure manufacturing, logistics, and emergency preparedness.

Country Insights: Different Priorities Across Major Markets

The United States and Canada have established specialist networks and strong rare-disease research capacity, with access influenced by payer rules and prior authorization. The United Kingdom, France, Germany, Italy, and Spain combine advanced clinical expertise with country-specific health-technology and reimbursement processes. Australia emphasizes centralized evaluation and geographically distributed care. Japan and South Korea have sophisticated regulatory and hospital systems, while China is expanding specialized care and domestic biopharmaceutical capabilities. India faces marked variation between metropolitan specialty centers and broader populations. Brazil and Mexico are shaped by public-private healthcare differences and uneven specialist access. Russia’s pathway is influenced by domestic procurement, regulatory, and supply considerations.

Actions for Leaders: Build Evidence, Access, and Resilience Together

Industry leaders should prioritize clinically meaningful differentiation, including durable control, rapid onset, convenient administration, and outcomes that matter to patients. Evidence plans should address both acute treatment and prevention where appropriate, use validated endpoints, and include diverse populations. Early engagement with regulators, payers, patient organizations, and specialist networks can clarify evidence expectations. Commercial and medical teams should invest in diagnostic education, referral pathways, pharmacovigilance, and reliable cold-chain or specialty distribution requirements. Scenario planning should also address manufacturing redundancy, cybersecurity, geopolitical disruption, and equitable access in lower-resource settings.

Methodology: Evidence-Led Synthesis of the Kallikrein-Inhibitor Field

This executive summary uses a qualitative synthesis framework centered on the biology of kallikrein inhibition, clinical-use contexts, development trends, healthcare-system conditions, and policy considerations. Interpretation should be grounded in peer-reviewed research, clinical guidelines, regulatory documents, trial registries, pharmacovigilance sources, and publicly available health-system information. Regional, group, and country comparisons are presented as contextual observations rather than quantified rankings. No market estimates, market shares, forecasts, or company-specific assessments are used.

Conclusion: Precision and Access Will Define Sustainable Progress

Kallikrein inhibitors sit at the intersection of validated pathway biology, rare-disease care, and broader therapeutic innovation. Progress will depend on translating mechanistic selectivity into dependable patient outcomes while improving diagnosis, administration, affordability, and continuity of supply. Organizations that combine rigorous evidence generation with responsible AI use, regional adaptation, and resilient access strategies will be best positioned to advance the field without compromising safety or equity.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Kallikrein Inhibitors Market, by Type
7.1. Introduction
7.2. Plasma Kallikrein Inhibitors
7.3. Tissue Kallikrein Inhibitors
8. Kallikrein Inhibitors Market, by Administration Route
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Kallikrein Inhibitors Market, by End User
9.1. Introduction
9.2. Home Care Settings
9.3. Hospitals
9.4. Specialty Clinics
10. Kallikrein Inhibitors Market, by Indication
10.1. Introduction
10.2. Diabetic Macular Edema
10.3. Hereditary Angioedema
11. Kallikrein Inhibitors Market, by Molecular Entity
11.1. Introduction
11.2. Berotralstat
11.3. Ecallantide
11.4. Lanadelumab
12. Kallikrein Inhibitors Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Kallikrein Inhibitors Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Kallikrein Inhibitors Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. ActiveSite Pharmaceuticals, Inc.
16.2. ADARx Pharmaceuticals, Inc.
16.3. Alkem Laboratories Ltd.
16.4. Bayer AG
16.5. BioCryst Pharmaceuticals, Inc.
16.6. Dr. Reddy's Laboratories Ltd.
16.7. Dyax Corp.
16.8. Fresenius Kabi AG
16.9. Hangzhou Bolin Pharmaceutical Technology Co., Ltd.
16.10. Hikma Pharmaceuticals PLC
16.11. Intellia Therapeutics, Inc.
16.12. Ionis Pharmaceuticals, Inc.
16.13. KalVista Pharmaceuticals, Inc.
16.14. Merck KGaA (Merck Group)
16.15. Novartis AG
16.16. Oxurion NV
16.17. Pfizer Inc.
16.18. Rezolute, Inc.
16.19. Takeda Pharmaceutical Company Limited
16.20. United Biotech (P) Ltd.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Kallikrein Inhibitors Market, Years Considered for the Study
FIGURE 2. Global Kallikrein Inhibitors Market, Research Design
FIGURE 3. Global Kallikrein Inhibitors Market, Research Framework
FIGURE 4. Global Kallikrein Inhibitors Market, Data Triangulation
FIGURE 5. Global Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Kallikrein Inhibitors Market Size, by Type, 2025 vs 2032 (%)
FIGURE 7. Global Kallikrein Inhibitors Market Size, by Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Kallikrein Inhibitors Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 9. Global Kallikrein Inhibitors Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Kallikrein Inhibitors Market Size, by End User, 2025 vs 2032 (%)
FIGURE 11. Global Kallikrein Inhibitors Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Kallikrein Inhibitors Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 13. Global Kallikrein Inhibitors Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Kallikrein Inhibitors Market Size, by Molecular Entity, 2025 vs 2032 (%)
FIGURE 15. Global Kallikrein Inhibitors Market Size, by Molecular Entity, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Kallikrein Inhibitors Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Kallikrein Inhibitors Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Kallikrein Inhibitors Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Kallikrein Inhibitors Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Kallikrein Inhibitors Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Kallikrein Inhibitors Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Kallikrein Inhibitors Market Segmentation & Coverage
TABLE 2. Global Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 3. Global Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 4. Global Plasma Kallikrein Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Plasma Kallikrein Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Plasma Kallikrein Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Tissue Kallikrein Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Tissue Kallikrein Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Tissue Kallikrein Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 11. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Parenteral Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Parenteral Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Parenteral Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 18. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 19. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 20. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 21. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 28. Global Diabetic Macular Edema Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Diabetic Macular Edema Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Diabetic Macular Edema Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Hereditary Angioedema Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Hereditary Angioedema Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Hereditary Angioedema Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 35. Global Berotralstat Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Berotralstat Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Berotralstat Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Ecallantide Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Ecallantide Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Ecallantide Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Lanadelumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Lanadelumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Lanadelumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Kallikrein Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Asia-Pacific Kallikrein Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Asia-Pacific Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 47. Asia-Pacific Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 48. Asia-Pacific Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 49. Asia-Pacific Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 50. Asia-Pacific Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 51. North America Kallikrein Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. North America Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 53. North America Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 54. North America Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 55. North America Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 56. North America Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 57. Latin America Kallikrein Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Latin America Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 59. Latin America Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 60. Latin America Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 61. Latin America Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 62. Latin America Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 63. Europe Kallikrein Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Europe Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 65. Europe Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 66. Europe Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 67. Europe Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 68. Europe Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 69. Middle East Kallikrein Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Middle East Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 71. Middle East Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 72. Middle East Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 73. Middle East Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 74. Middle East Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 75. Africa Kallikrein Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Africa Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 77. Africa Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 78. Africa Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 79. Africa Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 80. Africa Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 81. Global Kallikrein Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. ASEAN Kallikrein Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. ASEAN Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 84. ASEAN Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 85. ASEAN Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. ASEAN Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 87. ASEAN Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 88. GCC Kallikrein Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. GCC Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 90. GCC Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 91. GCC Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 92. GCC Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 93. GCC Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 94. European Union Kallikrein Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. European Union Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 96. European Union Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 97. European Union Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. European Union Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 99. European Union Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 100. BRICS Kallikrein Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. BRICS Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 102. BRICS Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 103. BRICS Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 104. BRICS Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 105. BRICS Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 106. G7 Kallikrein Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. G7 Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 108. G7 Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 109. G7 Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. G7 Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 111. G7 Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 112. NATO Kallikrein Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. NATO Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 114. NATO Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 115. NATO Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. NATO Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 117. NATO Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 118. Global Kallikrein Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. United States Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 120. United States Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 121. United States Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 122. United States Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 123. United States Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 124. United States Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 125. Canada Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 126. Canada Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 127. Canada Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 128. Canada Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 129. Canada Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 130. Canada Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 131. Mexico Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 132. Mexico Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 133. Mexico Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 134. Mexico Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. Mexico Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 136. Mexico Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 137. Brazil Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 138. Brazil Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 139. Brazil Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 140. Brazil Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. Brazil Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 142. Brazil Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 143. United Kingdom Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 144. United Kingdom Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 145. United Kingdom Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 146. United Kingdom Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 147. United Kingdom Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 148. United Kingdom Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 149. Germany Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 150. Germany Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 151. Germany Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 152. Germany Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. Germany Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 154. Germany Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 155. France Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 156. France Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 157. France Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 158. France Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. France Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 160. France Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 161. Russia Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 162. Russia Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 163. Russia Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 164. Russia Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. Russia Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 166. Russia Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 167. Italy Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 168. Italy Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 169. Italy Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 170. Italy Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. Italy Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 172. Italy Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 173. Spain Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 174. Spain Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 175. Spain Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 176. Spain Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. Spain Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 178. Spain Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 179. China Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 180. China Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 181. China Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 182. China Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 183. China Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 184. China Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 185. India Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 186. India Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 187. India Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 188. India Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 189. India Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 190. India Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 191. Japan Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 192. Japan Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 193. Japan Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 194. Japan Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. Japan Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 196. Japan Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 197. Australia Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 198. Australia Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 199. Australia Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 200. Australia Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. Australia Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 202. Australia Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 203. South Korea Kallikrein Inhibitors Market Size, 2017-2032 (USD Million)
TABLE 204. South Korea Kallikrein Inhibitors Market Size, by Type, 2017-2032 (USD Million)
TABLE 205. South Korea Kallikrein Inhibitors Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 206. South Korea Kallikrein Inhibitors Market Size, by End User, 2017-2032 (USD Million)
TABLE 207. South Korea Kallikrein Inhibitors Market Size, by Indication, 2017-2032 (USD Million)
TABLE 208. South Korea Kallikrein Inhibitors Market Size, by Molecular Entity, 2017-2032 (USD Million)
TABLE 209. Global Kallikrein Inhibitors Market Share, by Key Player, 2025
TABLE 210. Global Kallikrein Inhibitors Market, Key Experts

Companies Mentioned

  • ActiveSite Pharmaceuticals, Inc.
  • ADARx Pharmaceuticals, Inc.
  • Alkem Laboratories Ltd.
  • Bayer AG
  • BioCryst Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Dyax Corp.
  • Fresenius Kabi AG
  • Hangzhou Bolin Pharmaceutical Technology Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Merck KGaA (Merck Group)
  • Novartis AG
  • Oxurion NV
  • Pfizer Inc.
  • Rezolute, Inc.
  • Takeda Pharmaceutical Company Limited
  • United Biotech (P) Ltd.

Related Topics

Related Reports

HAE Treatments Market - Global Forecast 2026-2032 - Product Image

HAE Treatments Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Hereditary Angioedema Therapeutics Market - Global Forecast 2026-2032 - Product Image

Hereditary Angioedema Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Hereditary Angioedema Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Hereditary Angioedema Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 110 Pages
  • Global
From
Hereditary Angioedema Therapeutic Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035) - Product Image

Hereditary Angioedema Therapeutic Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

  • Report
  • 350 Pages
  • Global
From
Hereditary Angioedema Therapeutics Market Size, Share & Trends Analysis Report by Treatment, End Use, Region, and Growth Forecasts, 2026-2033 - Product Image

Hereditary Angioedema Therapeutics Market Size, Share & Trends Analysis Report by Treatment, End Use, Region, and Growth Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.